Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
3.540
-0.010 (-0.28%)
At close: Jun 27, 2025, 4:00 PM
3.550
+0.010 (0.28%)
After-hours: Jun 27, 2025, 4:34 PM EDT
Cytek Biosciences Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Cytek Biosciences stock ranges from a low of $3.00 to a high of $8.00. The average analyst price target of $6.00 forecasts a 69.49% increase in the stock price over the next year.
Price Target: $6.00 (+69.49%)
Analyst Consensus: Hold
* Price targets were last updated on May 28, 2025.
Analyst Ratings
The average analyst rating for Cytek Biosciences stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Total | 3 | 3 | 2 | 2 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $9 → $7 | Hold | Maintains | $9 → $7 | +97.74% | May 28, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $3.5 → $3 | Strong Sell | Maintains | $3.5 → $3 | -15.25% | May 12, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $6 | Buy | Reiterates | $6 | +69.49% | Mar 19, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $8.5 → $8 | Buy | Maintains | $8.5 → $8 | +125.99% | Mar 4, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $8.5 | Buy | Maintains | $8 → $8.5 | +140.11% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
202.27M
from 200.45M
Increased by 0.91%
Revenue Next Year
217.95M
from 202.27M
Increased by 7.75%
EPS This Year
-0.22
from -0.05
EPS Next Year
-0.16
from -0.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 209.6M | 234.1M | 273.2M |
| Avg | 202.3M | 218.0M | 248.9M |
| Low | 192.1M | 196.7M | 228.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 4.6% | 15.8% | 25.4% |
| Avg | 0.9% | 7.8% | 14.2% |
| Low | -4.2% | -2.8% | 4.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.09 | -0.07 | -0.06 |
| Avg | -0.22 | -0.16 | -0.10 |
| Low | -0.31 | -0.21 | -0.14 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.